{
    "clinical_study": {
        "@rank": "45118", 
        "acronym": "Quad", 
        "arm_group": [
            {
                "arm_group_label": "Historical healthy control subjects", 
                "description": "Historical healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline."
            }, 
            {
                "arm_group_label": "ART-na\u00efve HIV+ patients starting QUAD/Stribild", 
                "description": "ART-na\u00efve HIV+ patients who are about to be started QUAD/Stribild by their treating clinicians will be studied at baseline and 6 months after initiating QUAD/Stribild therapy."
            }
        ], 
        "biospec_descr": {
            "textblock": "Plasma, serum."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The main aims of this study are to determine whether: a) ART-na\u00efve HIV+ subjects have\n      increased artherosclerotic plaque inflammation/vulnerability, b) newly-initiated\n      QUAD/Stribild therapy will decrease plaque inflammation/vulnerability in these subjects, and\n      c) QUAD/Stribild therapy will improve indices of immune dysregulation and lipid dysfunction\n      as a mechanism of improved plaque inflammation/vulnerability."
        }, 
        "brief_title": "Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Na\u00efve Infected Patients", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV", 
        "condition_browse": {
            "mesh_term": "Inflammation"
        }, 
        "detailed_description": {
            "textblock": "Patients with HIV are at higher risk of morbidity and mortality from cardiovascular disease\n      than healthy subjects. Antiretroviral therapy (ART) has greatly increased the lifespan of\n      HIV+ patients, but their risk of CVD remains higher than normal. Previously, it has been\n      shown that compared to healthy control subjects, ART-treated HIV+ patients have more\n      atherosclerotic plaque inflammation in the aorta. This study is intended to determine\n      whether atherosclerotic plaque inflammation/vulnerability is increased in ART-na\u00efve HIV+\n      patients and whether these parameters can be improved through 6 months of newly-initiated\n      QUAD/Stribild therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  men and women, ages 18+, with documented HIV-infection who are ART-naive and ready to\n             be started on ART with QUAD/Stribild by their treating infectious disease doctors\n\n        Exclusion Criteria:\n\n          -  history of prior, sustained ART use\n\n          -  CD4 <50 or AIDS-defining illness\n\n          -  known current opportunistic infection or acute infections (not including Hepatitis\n             B/C)\n\n          -  pregnancy or breastfeeding\n\n          -  history of acute coronary syndrome or coronary artery stenting or surgery, diabetes\n             mellitus, or significant autoimmune/inflammatory disease\n\n          -  plans for sustained use during 6 month study interval of a confounding immune\n             suppressant medication including intravenous or oral corticosteroid\n\n          -  hemoglobin < 12.5 for men or < 12 for women\n\n          -  eGFR < 70 ml/min/1.73 m2  calculated by CDK-EPI\n\n          -  contrast dye allergy\n\n          -  contraindication to beta blockers or nitroglycerin administered during MDCT coronary\n             angiography (coronary CTA) protocol\n\n          -  body weight > 320 lbs (PET scanner limitation)\n\n          -  significant radiation exposure (>2 myocardial perfusion scans or CT angiograms)\n             received within the past year\n\n          -  reported active illicit drug use"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects with HIV infection being cared for in the Eastern Massachusetts area may be\n        appprised of the study by their treating infectious disease doctors. Additionally,\n        subjects with HIV infection from the community will be recruited via posters,\n        advertisements, e-postings."
            }
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01766726", 
            "org_study_id": "2012P001138"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV", 
            "Atherosclerosis"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "contact": {
                "email": "sgrinspoon@partners.org", 
                "last_name": "Steven K Grinspoon, MD", 
                "phone": "617-724-9109"
            }, 
            "contact_backup": {
                "email": "mzanni@partners.org", 
                "last_name": "Markella V Zanni, MD", 
                "phone": "617-724-6926"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Na\u00efve Infected Patients", 
        "overall_contact": {
            "email": "sgrinspoon@partners.org", 
            "last_name": "Steven K Grinspoon, MD", 
            "phone": "617-724-9109"
        }, 
        "overall_contact_backup": {
            "email": "mzanni@partners.org", 
            "last_name": "Markella V Zanni, MD", 
            "phone": "617-724-6926"
        }, 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Steven K Grinspoon, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Degree of aortic/coronary atherosclerotic plaque inflammation assessed via cardiac FDG-PET as target to background ratio (TBR) of the standardized uptake value (SUV).", 
            "measure": "Aortic/coronary target to background ratio (TBR) on cardiac FDG-PET", 
            "safety_issue": "No", 
            "time_frame": "Baseline and change from baseline to 6 months in HIV cohort starting QUAD/Stribild"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01766726"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Steven K. Grinspoon, MD", 
            "investigator_title": "Professor of Medicine, Harvard Medical School", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Aortic/coronary atherosclerotic plaque assessed via coronary CTA.", 
                "measure": "Aortic/coronary atherosclerotic plaque on coronary computed tomography angiography (coronary CTA)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and change from baseline to 6 months in HIV cohort starting QUAD/Stribild"
            }, 
            {
                "description": "Levels of lipids and lipoproteins including but not limited to levels of total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and levels select apolipoprotein levels.", 
                "measure": "Lipid and lipoprotein levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline and change from baseline to 6 months in HIV cohort starting QUAD/Stribild"
            }, 
            {
                "description": "HDL oxidative potential.", 
                "measure": "Indices of pro-atherogenic lipid dysfunction", 
                "safety_issue": "No", 
                "time_frame": "Baseline and change from baseline to 6 months in HIV cohort starting QUAD/Stribild"
            }, 
            {
                "description": "Levels of inflammatory biomarkers including but not limited to soluble CD163.", 
                "measure": "Inflammatory biomarker levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline and change from baseline to 6 months in HIV cohort starting QUAD/Stribild"
            }, 
            {
                "description": "Percentage of circulating activated leukocyte subsets including but not limited to percentage of circulating CD14+CD16+ monocytes assessed via flow cytometry.", 
                "measure": "Percentage of circulating activated leukocyte subsets", 
                "safety_issue": "No", 
                "time_frame": "Baseline and change from baseline to 6 months in HIV cohort starting QUAD/Stribild"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}